Trial Search Results

Clinical Study to Investigate the Long-term Safety, Tolerability, and Efficacy of Ponesimod in Patients With Relapsing-remitting Multiple Sclerosis

This study is an extension to the study AC-058B201 and will investigate the long-term safety, tolerability and efficacy of ponesimod in patients with relapsing-remitting multiple sclerosis.

Stanford is currently not accepting patients for this trial.

Lead Sponsor:

Actelion

Stanford Investigator(s):

Intervention(s):

  • Drug: Ponesimod 10 mg
  • Drug: Ponesimod 20 mg
  • Drug: Ponesimod 40 mg

Phase:

Phase 2

Eligibility


Inclusion Criteria:

   1. Patients who completed study treatment at their regular Week 24 (End of treatment)
   visit within the core study AC-058B201.

   2. Signed informed consent for participating in the extension study.

Exclusion Criteria:

1. Any clinically relevant medical or surgical condition, which, in the opinion of the
investigator, would put the patient at risk by participating in the extension study.

Ages Eligible for Study

18 Years - 55 Years

Genders Eligible for Study

All

Not currently accepting new patients for this trial

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Angela Campbell
(650) 721-6188
Not Recruiting